Special Issue

Lung Cancer: Updates on Therapy and Prognostic Prediction

Message from the Guest Editor

Lung cancer remains one of the most prevalent and deadliest forms of cancer worldwide, representing a significant challenge for healthcare systems across the globe. Despite advancements in diagnostic methods and therapeutic approaches, lung cancer continues to account for the highest number of cancer-related deaths, largely due to late-stage diagnosis and its aggressive nature. Early detection and reliable prognostic models are essential for optimizing treatment decisions, improving outcomes, and reducing unnecessary treatment-related toxicities. Emerging biomarkers, artificial intelligence-driven prediction models, and next-generation sequencing are paving the way for more precise and personalized prognostic tools. In this Special Issue, original research articles and reviews are welcome. We aim to highlight innovative treatment strategies, novel approaches to prognostic prediction, and the latest advancements in lung cancer management. By bringing together cutting-edge research in these critical areas, this Issue seeks to provide a comprehensive update that will inform clinical practice and shape future research in the management of lung cancer.

Guest Editor

Prof. Dr. Servet Bölükbas

1. Department of Thoracic Surgery, Medical Faculty, West German Cancer Center, University Medicine Essen-Ruhrlandklinik, Tueschner Weg 40, 45239 Essen, Germany
2. National Center for Tumor Diseases (NCT) West, Essen, Germany

Deadline for manuscript submissions

31 October 2025

Cancers

mdpi.com/journal/cancers

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)